327 related articles for article (PubMed ID: 23833274)
41. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
Polyzos SA; Kountouras J; Zavos C; Tsiaousi E
Diabetes Obes Metab; 2010 May; 12(5):365-83. PubMed ID: 20415685
[TBL] [Abstract][Full Text] [Related]
42. Inflammation in nonalcoholic steatohepatitis.
Harmon RC; Tiniakos DG; Argo CK
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):189-200. PubMed ID: 21476914
[TBL] [Abstract][Full Text] [Related]
43. Non-alcoholic fatty liver disease.
Smith BW; Adams LA
Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
[TBL] [Abstract][Full Text] [Related]
44. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.
Iacono A; Raso GM; Canani RB; Calignano A; Meli R
J Nutr Biochem; 2011 Aug; 22(8):699-711. PubMed ID: 21292470
[TBL] [Abstract][Full Text] [Related]
45. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes.
Grønbaek H; Thomsen KL; Rungby J; Schmitz O; Vilstrup H
Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):705-11. PubMed ID: 19072347
[TBL] [Abstract][Full Text] [Related]
46. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?
Ahmed MH; Ali A
Scand J Gastroenterol; 2014 May; 49(5):521-7. PubMed ID: 24646400
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
Polyzos SA; Kountouras J; Zavos C
Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
[TBL] [Abstract][Full Text] [Related]
48. Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver.
Takamura T; Misu H; Ota T; Kaneko S
Endocr J; 2012; 59(9):745-63. PubMed ID: 22893453
[TBL] [Abstract][Full Text] [Related]
49. Roles of Chemokines and Chemokine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic Fatty Liver Disease.
Xu L; Kitade H; Ni Y; Ota T
Biomolecules; 2015 Jul; 5(3):1563-79. PubMed ID: 26197341
[TBL] [Abstract][Full Text] [Related]
50. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling.
Shabalala SC; Dludla PV; Mabasa L; Kappo AP; Basson AK; Pheiffer C; Johnson R
Biomed Pharmacother; 2020 Nov; 131():110785. PubMed ID: 33152943
[TBL] [Abstract][Full Text] [Related]
51. Nonalcoholic fatty liver disease: biochemical and therapeutic considerations.
Patrick-Melin AJ; Kalinski MI; Kelly KR; Haus JM; Solomon TP; Kirwan JP
Ukr Biokhim Zh (1999); 2009; 81(5):16-25. PubMed ID: 20387643
[TBL] [Abstract][Full Text] [Related]
52. Gut Microbiota: Association with NAFLD and Metabolic Disturbances.
Lau E; Carvalho D; Freitas P
Biomed Res Int; 2015; 2015():979515. PubMed ID: 26090468
[TBL] [Abstract][Full Text] [Related]
53. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract.
Derra A; Bator M; Menżyk T; Kukla M
Clin Exp Hepatol; 2018 Jun; 4(2):55-71. PubMed ID: 29904722
[TBL] [Abstract][Full Text] [Related]
54. Psoriasis and non-alcoholic fatty liver disease.
Wenk KS; Arrington KC; Ehrlich A
J Eur Acad Dermatol Venereol; 2011 Apr; 25(4):383-91. PubMed ID: 20840346
[TBL] [Abstract][Full Text] [Related]
55. Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies.
Morrison MC; Kleemann R
Front Immunol; 2015; 6():308. PubMed ID: 26124760
[TBL] [Abstract][Full Text] [Related]
56. Causes and metabolic consequences of Fatty liver.
Stefan N; Kantartzis K; Häring HU
Endocr Rev; 2008 Dec; 29(7):939-60. PubMed ID: 18723451
[TBL] [Abstract][Full Text] [Related]
57. Roles of liver innate immune cells in nonalcoholic fatty liver disease.
Zhan YT; An W
World J Gastroenterol; 2010 Oct; 16(37):4652-60. PubMed ID: 20872965
[TBL] [Abstract][Full Text] [Related]
58. The lipid droplet as a potential therapeutic target in NAFLD.
Goh VJ; Silver DL
Semin Liver Dis; 2013 Nov; 33(4):312-20. PubMed ID: 24222089
[TBL] [Abstract][Full Text] [Related]
59. MicroRNAs in fatty liver disease.
Sobolewski C; Calo N; Portius D; Foti M
Semin Liver Dis; 2015 Feb; 35(1):12-25. PubMed ID: 25632931
[TBL] [Abstract][Full Text] [Related]
60. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease.
Kumashiro N; Erion DM; Zhang D; Kahn M; Beddow SA; Chu X; Still CD; Gerhard GS; Han X; Dziura J; Petersen KF; Samuel VT; Shulman GI
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16381-5. PubMed ID: 21930939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
